
icon
-
Media Release
FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)
-
Media Release
Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA-positive metastatic castration-resistant prostate cancer
-
Media Release
FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
-
StoryTelemedicine is helping patients in underserved communities access quality healthcare
-
StoryAt-home app helps patients stay engaged and adherent to vision monitoring remotely
Pagination
- ‹ Previous page
- 1
- …
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- › Next page